An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients

Trial Profile

An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2017

At a glance

  • Drugs Maraviroc (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms POEM
  • Sponsors Pfizer; ViiV Healthcare
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 31 Oct 2018 to 26 Feb 2019.
    • 28 Jun 2017 Planned primary completion date changed from 31 Oct 2018 to 26 Feb 2019.
    • 17 May 2017 Planned End Date changed from 1 Oct 2018 to 31 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top